128 related articles for article (PubMed ID: 33811172)
1. Drug-Wide Association Study (DWAS): Challenges and Opportunities.
Wang Y; Gadalla SM
Cancer Epidemiol Biomarkers Prev; 2021 Apr; 30(4):597-599. PubMed ID: 33811172
[TBL] [Abstract][Full Text] [Related]
2. Drug Use and Cancer Risk: A Drug-Wide Association Study (DWAS) in Norway.
Støer NC; Botteri E; Thoresen GH; Karlstad Ø; Weiderpass E; Friis S; Pottegård A; Andreassen BK
Cancer Epidemiol Biomarkers Prev; 2021 Apr; 30(4):682-689. PubMed ID: 33144282
[TBL] [Abstract][Full Text] [Related]
3. Tumour-agnostic drugs in paediatric cancers.
Chisholm JC; Carceller F; Marshall LV
Br J Cancer; 2020 May; 122(10):1425-1427. PubMed ID: 32161367
[TBL] [Abstract][Full Text] [Related]
4. Developing Drugs for Tissue-Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine.
Seligson ND; Knepper TC; Ragg S; Walko CM
Clin Pharmacol Ther; 2021 Feb; 109(2):334-342. PubMed ID: 32535906
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Noncancer Drug Effects on Survival in Electronic Health Records of Patients With Cancer: A New Paradigm for Drug Repurposing.
Wu Y; Warner JL; Wang L; Jiang M; Xu J; Chen Q; Nian H; Dai Q; Du X; Yang P; Denny JC; Liu H; Xu H
JCO Clin Cancer Inform; 2019 May; 3():1-9. PubMed ID: 31141421
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness of internet-based e-learning on clinician behavior and patient outcomes: a systematic review protocol.
Sinclair P; Kable A; Levett-Jones T
JBI Database System Rev Implement Rep; 2015 Jan; 13(1):52-64. PubMed ID: 26447007
[TBL] [Abstract][Full Text] [Related]
7. The project data sphere initiative: accelerating cancer research by sharing data.
Green AK; Reeder-Hayes KE; Corty RW; Basch E; Milowsky MI; Dusetzina SB; Bennett AV; Wood WA
Oncologist; 2015 May; 20(5):464-e20. PubMed ID: 25876994
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide association studies of cancer: current insights and future perspectives.
Sud A; Kinnersley B; Houlston RS
Nat Rev Cancer; 2017 Nov; 17(11):692-704. PubMed ID: 29026206
[TBL] [Abstract][Full Text] [Related]
9. Validation of a pediatric asthma caregiver diary.
Santanello NC; Demuro-Mercon C; Davies G; Ostrom N; Noonan M; Rooklin A; Knorr B
J Allergy Clin Immunol; 2000 Nov; 106(5):861-6. PubMed ID: 11080707
[TBL] [Abstract][Full Text] [Related]
10. Ammonia-methane two-stage anaerobic digestion of dehydrated waste-activated sludge.
Nakashimada Y; Ohshima Y; Minami H; Yabu H; Namba Y; Nishio N
Appl Microbiol Biotechnol; 2008 Jul; 79(6):1061-9. PubMed ID: 18491038
[TBL] [Abstract][Full Text] [Related]
11. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
Workman P
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
[TBL] [Abstract][Full Text] [Related]
12. Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs.
Balogh EP; Bindman AB; Eckhardt SG; Halabi S; Harvey RD; Jaiyesimi I; Miksad R; Moses HL; Nass SJ; Schilsky RL; Sun S; Torrente JM; Warren KE
Oncologist; 2020 Mar; 25(3):e405-e411. PubMed ID: 32162805
[TBL] [Abstract][Full Text] [Related]
13. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Patient Medication Adherence, Medical Record Accuracy, and Medication Blood Concentrations for Prescription and Over-the-Counter Medications.
Sutherland JJ; Morrison RD; McNaughton CD; Daly TM; Milne SB; Daniels JS; Ryan TP
JAMA Netw Open; 2018 Nov; 1(7):e184196. PubMed ID: 30646345
[TBL] [Abstract][Full Text] [Related]
15. The post hoc use of randomised controlled trials to explore drug associated cancer outcomes: methodological challenges.
Stefansdottir G; Zoungas S; Chalmers J; Knol MJ; Leufkens HG; Woodward M; Patel A; Grobbee DE; De Bruin ML
Curr Drug Saf; 2013 Nov; 8(5):371-8. PubMed ID: 24215314
[TBL] [Abstract][Full Text] [Related]
16. Methodological and conceptual issues regarding occupational psychosocial coronary heart disease epidemiology.
Burr H; Formazin M; Pohrt A
Scand J Work Environ Health; 2016 May; 42(3):251-5. PubMed ID: 26960179
[TBL] [Abstract][Full Text] [Related]
17. Challenges in evaluating cancer as a clinical outcome in postapproval studies of drug safety.
Pinheiro SP; Rivera DR; Graham DJ; Freedman AN; Major JM; Penberthy L; Levenson M; Bradley MC; Wong HL; Ouellet-Hellstrom R
Ann Epidemiol; 2016 Nov; 26(11):735-740. PubMed ID: 27663208
[TBL] [Abstract][Full Text] [Related]
18. Accelerating anticancer drug development - opportunities and trade-offs.
Nass SJ; Rothenberg ML; Pentz R; Hricak H; Abernethy A; Anderson K; Gee AW; Harvey RD; Piantadosi S; Bertagnolli MM; Schrag D; Schilsky RL
Nat Rev Clin Oncol; 2018 Dec; 15(12):777-786. PubMed ID: 30275514
[TBL] [Abstract][Full Text] [Related]
19. Tumor physiology and delivery of nanopharmaceuticals.
Campbell RB
Anticancer Agents Med Chem; 2006 Nov; 6(6):503-12. PubMed ID: 17100555
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
